Switching from zidovudine to didanosine in patients with symptomatic HIV infection and disease progression

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 12, Issue 3, 1996, Pages 249-258

  Gatell, José M ^a,j   González Lahoz, Juan ^c,f   Clotet, Bonaventura ^b   Antunes, Francisco ^d   Kasparova, Ludmila ^e   Gil Aguado, Antonio ^c,f   Saballs, Pere ^g   Santamaria, Juan M ^h   Podzamczer, Daniel ⁱ   Miro, José M ^k   Jou, Antoni ^b   Verdejo, Jose ^c,f   Doroana, Manuela ^d   Thomis, Jeff ^e  

^a Hospital Clinic   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^c Servicio de Enferemdades Infecciosas   (Spain)

^d Faculdade'De Medicina Veterinaria   (Portugal)

^e BRISTOL MYERS SQUIBB   (United States)

^f HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^g HOSPITAL DEL MAR   (Spain)

^h HOSPITAL DE BASURTO   (Spain)

ⁱ HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^j HOSPITAL CLÍNIC   (Spain)

^k NONE

more..

Author keywords

Didanosine; Symptomatic disease; Zidovudine

Indexed keywords

DIDANOSINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AIDS RELATED COMPLEX; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PANCREATITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 1542429700     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199607000-00004     Document Type: Article

References (24)

1. Mitsuya H, Broder S. Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy virus-associated virus (HTLV-III/ LAV) by 2′, 3′-dideoxynucleosides. Proc Natl Acad Sci USA 1986;83:1911-5.
2. Yarchoan R, Mitsuya H, Thomas RV, et al. In vivo activity against HIV and favorable toxicity profile of 2′, 3′-dideoxyinosine. Science 1989;245:412-5.
3. Cooley TP, Kunches LM, Saunders CA, et al. Treatment of AIDS and AIDS related complex with 2′, 3′-dideoxyinosine given once daily. Rev Infect Dis 1990;12(Suppl 5):S552-60.
4. Yarchoan R, Mitsuya H, Thomas RV, et al. In vivo activity against HIV and favourable toxicity profile of 2′, 3′-dideoxyinosine. Science 1989;245:412-5.
5. Yarchoan R, Pluda JM, Thomas RV, et al. Long term activity/toxicity profile of 2′, 3′-dideoxyinosine in AIDS or AIDS-related complex. Lancet 1990;336:526-9.
6. Cooley TP, Kunches LM, Saunders CA, et al. Once daily administration of 2′, 3′-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS related complex. N Engl J Med 1990;322:1340-4.
7. Lambert JS, Seidlin M, Reichman RC, et al. 2′, 3′-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS related complex. N Engl J Med 1990;322:1333-40.
8. Spruance SL, Pavia AT, Peterson D, et al. Didanosine compared with continuation of zidovudine in HIV-infected patients with signs of clinical deterioration while receiving zidovudine. Ann Intern Med 1994;120:360-8.
9. Kahn JO, Lagakos SW, Richman DD, et al. A controlled trial comparing continued ZDV with ddI in human immunodeficiency virus infection. N Engl J Med 1992;327:581-7.
10. Dolin R, Amato DA, Fischl MA, Pettinelli C, Beltangady M, Liou SH, et al. Zidovudine compared with didanosine in patients with advanced HIV type 1 infection and little or no previous experience with zidovudine. Arch Intern Med 1995;155:961-74.
11. Darbyshire JH, Aboulker JP. ddI for zidovudine-intolerant patients with HIV disease. Lancet 1992;340:1347-8.
12. 3. V European Conference on Clinical Aspects and treatment of HIV infection. Copenhagen, September 1995.
13. CDC. Revision of the CDC Surveillance Cure Definition for the Acquired Immune Deficiency Syndrome. MMWR 1987; 18:1-13.
14. Karnofsky DA, Abelmann WH, Craven LF, Borchenal JM. The use of the nitrogen mustards in the palliative treatment of carcinoma. Cancer 1948;1:634-56.
15. Freedman LS. Tables of the number of patients required in clinical trials using the log rank test. Stat Med 1982;1:121-9.
16. Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebocontrolled trial. N Engl J Med 1987;317:185-91.
17. Volberding PA, Lagakos SW, Koch MA, et al. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trials in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. N Engl J Med 1990;322:941-9.
18. Fischl MA, Richman DD, Hansen N, et al. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group. Ann Intern Med 1990; 112:727-37.
19. + lymphocytes are an incomplete surrogate marker for clinical progression in person with asymptomatic HIV infection taking zidovudine. Ann Intern Med 1993;118:674-80.
20. Knupp CA, Shyu WC, Dolin R, et al. Pharmacokinetics of didanosine in patients with acquired immunodeficiency syndrome or acquired immunodeficiency syndrome-related complex. Clin Pharmacol Ther 1991;49:523-35.
21. Shyu WC, Knupp CA, Pittman KA, et al. Food-induced reduction in bioavailability of didanosine. Clin Pharmacol Ther 1991;50:503-7.
22. Richman DD, Fischl MA, Grieco MH, et al. The toxicity of Azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med 1987;317:192-7.
23. Fischl MA, Richman DD, Causey DM, et al. Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. AZT Collaborative Working Group. JAMA 1989;262:2405-10.
24. Nordic Medical Research Council HIV Therapy Group. Double blind dose-response study of zidovudine in AIDS and advanced HIV infection. BMJ 1992;304:13-17.